Keivan Kiani - Cardiologist, Interventional Cardiology Research Center, Cardiovascular Research Institute, Isfahan University of Medicine Sciences, Isfahan, Iran
Hamidreza Roohafza - Psychosomatic Research Center, Isfahan University of Medicine Sciences, Isfahan, Iran
Mojgan Gharipour - Hypertension Research Center, Cardiovascular Research Institute, Isfahan University of Medicine Sciences, Isfahan, Iran
Minoo Dianatkhah - Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medicine Sciences, Isfahan, Iran
Mohammad Talaei - Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore
Shahram Oveisgharan - Department of Neurology, Tehran University of Medical Sciences, Tehran, Iran AND Alzheimer&#۰۳۹;s Disease Center, Rush University Medical Center, Chicago, IL
Nizal Sarrafzadegan - Professor, Department of Cardiology, Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
Masoumeh Sadeghi - Professor, Department of Cardiology, Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

BACKGROUND: Previous studies revealed that the level of ۲۵-hydroxyvitamin D [۲۵(OH)D] could be consider as one the risk factors for the occurrence of cardiovascular diseases (CVDs). This study aimed to evaluate the relationship between serum ۲۵(OH)D level and CVD events in individuals with and without metabolic syndrome (MetS) in an Iranian population.METHODS: In this nested case-control study conducted as a part of the Isfahan Cohort Study (ISC), ۵۵ patients with CVD events were selected as case group, and ۵۵ sex- and age-matched individuals without CVD events as control group. These participants were divided into the two main groups based on the presence of MetS at baseline.RESULTS: The level of ۲۵(OH)D in individuals with and without MetS was significantly lower among patients with CVD compared to those without CVD events at the baseline of study and after the follow-up (P = ۰.۰۳۶ and P = ۰.۰۳۹, respectively). The level of ۲۵(OH)D significantly decreased risk of incidence of CVD events in individuals without MetS after adjusting for age, sex, nutrition, and exposure to sunlight [۰.۱۹ (۰.۰۵-۰.۷۳); P = ۰.۰۱۶]. There was not any significant relationship between the amount of ۲۵(OH)D at the baseline and CVD events in individuals with MetS.CONCLUSION: In individuals with MetS, the level of ۲۵(OH)D is not related to CVD events; as MetS directly influence the pathophysiology of mechanisms which are responsible for CVD events, and maybe this effect obscure the effect of ۲۵(OH)D.

Cardiovascular Diseases, Metabolic Syndrome, ۲۵-Hydroxyvitamin D